FLT3 and acute myeloid leukemia: In this paper, we demonstrated that the expression level of integrin β3 was associated with the National Comprehensive Cancer Network (NCCN) risk stratification and could be a novel prognostic biomarker in AML especially in cytogenetic-normal FLT3-ITD mutated AML patients.